Citation:
Loh, A. H. P., Thura, M., Gupta, A., Tan, S. H., Kuan, K. K. Y., Ang, K. H., Merchant, K., Chang, K. T. E., Yon, H. Y., Chen, Y., Cheng, M. H. W., Mahadev, A., Ng, M. C. H., Seng, M. S.-F., Iyer, P., Chia, P. L., Soh, S. Y., & Zeng, Q. (2023). Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody. Molecular Therapy - Oncolytics, 30, 153–166. https://doi.org/10.1016/j.omto.2023.08.006